Ilaris 150 MG/ML vialml
Ended Awarded
- Contract number
- SPE2DB25FDL71
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $51,310
Award facts
- Contract value 100% obligated
- $51,310.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $51,310.04 to DMS Pharmaceutical Group Inc. for ILARIS 150 mg/mL vials on September 9, 2025. This firm fixed-price delivery order, with an ultimate completion date of September 30, 2025, represents a specific pharmaceutical supply requirement for federal healthcare systems. ILARIS (canakinumab) is a biologic medication used to treat inflammatory conditions, and this delivery falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at approximately $500 million through November 2026. The contract was awarded without a set-aside designation to the woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its extensive experience delivering branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. The company's robust portfolio of prior contract awards across diverse pharmaceutical products—ranging from specialty oncology treatments to vaccines and auto-injectors—demonstrates its capability to reliably fulfill the Defense Logistics Agency's complex medical supply requirements. This delivery order exemplifies the operational efficiency of the underlying IDC vehicle, enabling DLA to procure specific pharmaceutical items as needed to support military health facility operations globally.
Quick answers
Who was awarded contract SPE2DB25FDL71?
SPE2DB25FDL71 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 9, 2025.
How much is contract SPE2DB25FDL71 worth?
The government has obligated $51,310 on SPE2DB25FDL71.
Is contract SPE2DB25FDL71 an order under another contract?
Yes. SPE2DB25FDL71 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDL71 competed?
The extent of competition for SPE2DB25FDL71 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award